SBIR Phase I: A low-cost, bacterial production platform for the manufacturing of high purity recombinant proteins and growth factors

SBIR 第一阶段：用于制造高纯度重组蛋白和生长因子的低成本细菌生产平台

• 批准号: 2233507
• 负责人: Julie Liang
• 金额: $ 27.5万
• 依托单位: OPERA BIOSCIENCE, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-15 至 2024-09-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2233507&HistoricalAwards=false
• 关键词: SBIR; Phase; low; cost; bacterial

The broader/commercial impact of this Small Business Innovation Research (SBIR) Phase I project is to introduce a cost-effective way to produce recombinant proteins and growth factors for the cultivated meat industry. Cultivating animal cells to create animal tissues, including muscle and fat, allows manufacturers to create real animal meat as an alternative to animal-farmed meat. Producing meat in this method may provide a healthier, safer, and more ethical source of real animal meat. This manufacturing process avoids industrial animal farming and consequently uses significantly less land and water. It also avoids the greenhouse gases emitted by industrial animal farming and may emit far fewer greenhouse gases. Cultivated meat could result in a healthier public as well since its controlled production will likely result in fewer foodborne illnesses and avoid the cramped conditions of industrial animal farms that can breed new illnesses. The ability to grow meat in nearly any location increases the nation’s food supply chain resilience and reduces dependence on foreign food imports. Finally, by reducing the amount of industrial animal farms, cultivated meat reduces the need for animal slaughter.The proposed project will demonstrate the ability of the innovation to solve several challenges in the current production of recombinant proteins and growth factors in traditional protein manufacturing platforms that prevent manufacturing at lower costs and with high purity. Cultivated meat has the potential to disrupt the $1 trillion meat industry, but the ability to source high purity, cheap proteins limits the commercial adoption of cultivated meat products. The innovation could produce proteins at cheaper costs than existing platforms because it bypasses expensive and time-consuming operational manufacturing steps while still achieving high purity. The critical technical objectives of this project include: 1) the establishment and comparison of a production benchmark for recombinant growth factor production against the current industry standards, 2) the optimization of the growth conditions necessary for the protein production platform to achieve improved yields, and 3) the creation of a manufacturing platform optimization toolkit to increase the quality and amount of usable protein produced. The knowledge gained at the completion of this project may provide valuable insights into the ability and conditions to promote high production levels of proteins and growth factors while providing data illustrating the improvement when compared against current industry standards.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I阶段项目的更广泛/商业影响是引入一种具有成本效益的方式来为耕种肉类行业生产重组蛋白和生长因素。培养动物细胞以创建包括肌肉和脂肪在内的动物组织，使制造商可以创建真实的动物肉作为动物农场肉类的替代品。用这种方法生产肉可能会提供更健康，更安全，更符合真正的动物肉的来源。这种制造过程避免了工业动物的耕作，因此使用了较少的土地和水。它还避免了工业动物养殖产生的温室气体，并可能发出的温室气体少得多。耕种的肉也可能导致更健康的公众，因为其受控生产可能会导致更少的食源性疾病，并避免可以繁殖新疾病的工业动物农场的狭窄条件。在几乎任何位置种植肉的能力都会提高美国的粮食供应链的韧性，并降低对外国粮食进口的依赖。最后，通过减少工业动物农场的数量，栽培的肉减少了对动物屠杀的需求。拟议的项目将证明，在传统蛋白质制造平台中，创新解决了当前生产重组蛋白和生长因子在传统蛋白质制造平台中的一些挑战的能力，这些蛋白质以较低的成本和较高的纯度来防止制造。种植的肉有可能破坏1万亿美元的肉类行业，但廉价蛋白质的高纯度能力限制了商业采用种植的肉类产品。这项创新可以比现有平台以便宜的成本生产蛋白质，因为它绕过了昂贵且耗时的运营制造步骤，同时仍然可以实现高纯度。该项目的关键技术目标包括：1）建立和比较重组生长因子生产与当前行业标准的生产基准，2）蛋白质生产平台的优化优化蛋白质生产平台以提高产量的增长条件，3）创建制造平台优化工具包，以提高生产蛋白质的质量和数量。该项目完成后获得的知识可能会为促进蛋白质和生长因素的高生产水平的能力和条件提供宝贵的见解，同时提供数据，以说明与当前行业标准相比，该奖项反映了NSF的法定任务，并以评估基金会的知识分子和更广泛的影响来评估NSF的法定任务，并被视为珍贵的支持。